19th Nov 2015 11:40
LONDON (Alliance News) - Life sciences company ValiRx PLC on Thursday said the dose escalation portion of the phase 1/2 clinical trial for its VAL201 cancer compound is set to be completed.
The compound showed safety and tolerability in the trials and no significant adverse effects have been recorded, ValiRx said.
The company also said it has drafted the protocols and associated files to be submitted to start trials on its VAL401 compound.
Shares in ValiRx were down 4.1% to 23.01 pence on Thursday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
ValiRx